Syndax Pharmaceuticals (SNDX) Net Income towards Common Stockholders (2015 - 2026)

Syndax Pharmaceuticals' Net Income towards Common Stockholders history runs 12 years deep, the most recent figure standing at -$42.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 49.82% year-over-year to -$42.4 million; the TTM figure through Mar 2026 stood at -$212.7 million (up 37.07% YoY), while the FY2025 annual figure was -$307.2 million, up 46.31% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$42.4 million, down from -$34.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$34.0 million in Q4 2025, with the low at -$94.1 million in Q4 2024.
• The 5-year median for Net Income towards Common Stockholders is -$51.5 million (2023), against an average of -$57.9 million.
• The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders slumped 136.24% in 2022, then soared 63.85% in 2025.
• Syndax Pharmaceuticals' Net Income towards Common Stockholders stood at -$34.6 million in 2022, then sank by 65.42% to -$57.2 million in 2023, then sank by 64.7% to -$94.1 million in 2024, then jumped by 63.85% to -$34.0 million in 2025, then dropped by 24.73% to -$42.4 million in 2026.
• Business Quant data shows SNDX's Net Income towards Common Stockholders at -$42.4 million in Q1 2026, -$34.0 million in Q4 2025, and -$60.5 million in Q3 2025.